secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009854
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed rebrands to Definium Therapeutics; $412M cash; three Phase 3 readouts in 2026
--------------------------------------------------------------------------------

- Preliminary cash and investments ~$412M as of Dec 31, 2025.
- Name changed to Definium Therapeutics; new ticker DFTX effective Jan 13.
- Three Phase 3 readouts for DT120 ODT (GAD/MDD) in 2026: Voyage (2Q), Panorama (2H), Emerge (mid-year).
- Analyst Day in 2Q 2026 to highlight pipeline and path to commercialization.
- DT402 Phase 2a for autism spectrum disorder dosed first patient; initial data in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526009854/0001193125-26-009854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526009854/mnmd-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer